N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Conditions: Glioblastoma Interventions: Drug: Bevacizumab; Drug: PD-L1 t-haNK; Drug: N-803 Sponsors: ImmunityBio, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
Conditions: Metastatic Colorectal Cancer Interventions: Drug: Envafolimab; Drug: Trifluridine/Tipiracil; Drug: Bevacizumab Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Conditions: Diffuse Astrocytoma, IDH-Mutant; Glioblastoma, IDH-wildtype; Brain Metastases, Adult; Cervical Cancer; Colorectal Cancer; Esophageal Cancer; Esophageal Squamous Cell Carcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Head and Neck Squ amous Cell Carcinoma; Melanoma; Merkel Cell Carcinoma; Microsatellite Instability-High Solid Malignant Tumor; Mismatch Repair Deficient Solid Malignant Tumor; Microsatellite Instability-High Colorectal Cancer; Mismatch Repair Deficient Colorectal Cancer; Non-smal l Cell Lung Ca...
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
Conditions: Liver Transplant; Complications; Hepatocarcinoma; Recurrent Osteosarcoma; High-Risk Cancer Intervention: Drug: multi-kinase inhibitors in combination with bevacizumab Sponsor: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
